Rybelsus vs. Trulicity

Rybelsus (semaglutide) and Trulicity (semaglutide) Injection glucagon-like peptide-1 (GLP-1) receptor agonists used as adjuncts to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Side effects of Rybelsus and Trulicity that are similar include nausea, abdominal pain, diarrhea, vomiting, and constipation.

Side effects of Rybelsus that are different from Trulicity include decreased appetite.

Both Rybelsus and Trulicity may interact with insulin secretagogues or insulin, and other oral medications taken at the same time.

Common side effects of Rybelsus include:

• nausea,
• abdominal pain,
• diarrhea,
• decreased appetite,
• vomiting, and
• constipation

Common side effects of Trulicity include:

• nausea,
• diarrhea,
• frequent bowel movements,
• vomiting,
• abdominal pain or discomfort,
• decreased appetite,
• indigestion,
• fatigue,
• constipation,
• gas,
• bloating,
• gastroesophageal reflux disease (GERD),
• weakness/lack of energy,
• feeling unwell (malaise),
• belching, and
• low blood sugar (hypoglycemia).

Rybelsus (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Trulicity (dulaglutide) is a human GLP-1 receptor agonist used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Trulicity may interact with other drugs. Tell your doctor all medications and supplements you use.

Trulicity may interact with other oral medications. Tell your doctor all medications and supplements you use.

The initial dose of Rybelsus is 3 mg once daily for 30 days. After 30 days on the 3 mg dose, increase the dose of Rybelsus to 7 mg once daily.

The recommended initiating dose of Trulicity is 0.75 mg once weekly. The maximum recommended dose is 1.5 mg once weekly.